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Left ventricular diastolic dysfunction (LVDD) of the heart is a condition where the heart 
does not relax properly. This condition is important during times of stress, as LVDD is 
associated with significant morbidity of elderly surgical patients. LVDD is often 
asymptomatic and unrecognized as many of these patients have normal ejection 
fractions. However, LVDD may lead to heart failure in patients with preserved systolic 
function, with the incidence being as high as 50% in hospitalized elderly patients. The 
diagnosis of LVDD is an independent risk factor for postoperative major adverse cardiac 
events (MACE) and negatively impacts post-surgery readmission rates. 
Anesthesiologists play a critical role in the care of elderly patients by managing fluid 
therapy during surgery.  Current standard of care is to manage elderly patients with 
LVDD using only blood pressure monitoring. Unfortunately blood pressure monitoring is 
unable to detect changes in diastolic function, which fluid administration may affect. In 
contrast, transesophageal echocardiography (TEE) can easily measure diastolic function 
in real-time in the operating rooms. No current studies, however, have assessed 
changes to diastolic function in response to fluid boluses during noncardiac surgery. 
Therefore, it is important to serially evaluate LVDD intraoperatively with TEE and 
determine if changes in anesthetic management, specifically the response to fluid 
boluses, has effects on diastolic indices. The specific aim of this study is evaluate 
changes in left ventricular filling pressures and cardiac output in response to fluid 
boluses during the perioperative period. We predict echocardiographic diastolic indices 
are influenced by intraoperative fluid administration. 
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CHAPTER 1: INTRODUCTION 
Left ventricular diastolic dysfunction (LVDD) is a common disease in the rapidly 
growing elderly patient population and a major risk factor for heart failure (HF)1,2 3,4,5 In 
the United States, more Medicare dollars are spent on the diagnosis and treatment of 
HF than any other diagnosis.6 A recent study of 1000 elderly surgical patients found that 
LVDD was found preoperatively in 50% of patients undergoing vascular surgery, of 
which 80% were asymptomatic.7,8 Often asymptomatic, LVDD is an independent 
predictor of postoperative morbidity and mortality.9,10,11 Echocardiography is noninvasive 
and can measure diastolic function in real-time during the perioperative period. However, 
randomized clinical trials describing the use of echocardiography to guide intraoperative 
management have not been reported.8 Based on pilot data, we believe 
echocardiography-derived diastolic indices are influenced by anesthetic management; 
thus monitoring these indices and adjusting clinical algorithms accordingly can affect risk 
of postoperative major adverse cardiac events (MACE).  
LVDD and Anesthetic Management  
The goal of anesthesiologists taking care of elderly surgical patients is to 
maximize the patient’s circulatory function by optimizing cardiac output (CO) and 
ventricular filling pressures. The use of electrocardiogram (ECG) monitoring and 
systemic blood pressure is the standard of care for assessing circulatory function. 
However, these measurements are not barometers of diastolic function. Even the most 
invasive monitors, such as central venous pressure and pulmonary artery catheters 
(PACs), lack the ability to evaluate diastolic function and have not been shown to improve 
survival in elderly surgical patients.9,12 Because of the invasive nature of PACs and a lack 




these high-risk patients is left to noninvasive blood pressure monitoring, which can only 
serve as a surrogate measurement of filling pressures and CO. 
LVDD and Fluid Management 
Anesthesiologists are the perioperative primary care physicians of elderly 
patients undergoing more than 14 million procedures a year. They guide fluid 
management, alter vascular compliance, and treat sympathetic stimulation—all of which 
may impact clinical outcomes in patients with LVDD.13  With a diagnosis of diastolic 
dysfunction, a person accumulates approximately $110,000 in medical expenses over 
an average of four years from diagnosis to death. The average estimated LVDD-related 
hospitalization charge is $73,762 per person, with outpatient costs exceeding $25,000 
per person.6 While it is known that these older patients often have LVDD and that LVDD 
is an independent risk factor of mortality, it is not known how LVDD changes under 
standard operating conditions or if those changes influence or predict clinical 
outcomes.14 ,15 Standard guidelines or consensus statements on how to manage 
perioperative LVDD do not exist, despite billions in yearly health care expenditures.4 
Current anesthesia standards of care for fluid and drug management is no different in 
the elderly patient than the younger patient, even though elderly patients with LVDD 
undergoing surgery may need different fluid and drug management to optimize loading 
conditions. 
Background  
Previous investigations have shown that varying degrees of LVDD carry different 
risks of mortality; therefore, the ability to detect patients who are considered “high-risk” 
may lead to a change in current anesthesia practice. In a cross-sectional population study 




prevalence of diastolic dysfunction was over 20 percent and had an 8.31 times higher 
risk of mortality. Those with moderate (6.6% prevalence) and severe LVDD (0.7% 
prevalence) had 10.2 times higher mortality at 5 years compared with those with normal 
diastolic function.4 Grading of LVDD is commonly based on echocardiographic schema 
using transthoracic echocardiography (TTE). Guidelines from the American Society of 
Echocardiography (ASE) classify diastolic dysfunction into Grades I (Impaired 
Relaxation), Grade II (Pseudonormal) or Grade III (Restrictive).16 This grading system is 
often used to assess response to therapy in epidemiological studies with TTE; however, 
the utility for assessment of LVDD with transesophageal echocardiography (TEE) has 
recently been studied during cardiac surgery by Swaminathan and colleagues.5,15 Their 
retrospective study of over 900 patients found that a simple echo algorithm increased 
classification of LVDD and that worsening grades of LVDD were associated with higher 
adverse events.15 
Significance  
Although the grading of LVDD may differ in the operating room (OR) versus a 
“snapshot” on a screening TTE, studies into whether diastolic function can actually 
worsen or improve during surgery in response to fluid and drug therapy have not been 
completed. Although it is known that a worsening LVDD grade has a negative impact on 
mortality, it is not known how often the grade of LVDD changes in the dynamic operative 
room environment. Secondly, if LVDD grades are dynamic during surgery, can alterations 
in fluid and drug therapy based on these changes affect outcomes? This study will 
address these key questions: 





Our ability to detect and managing LVDD in the dynamic state of the OR is 
lacking.17 Few studies have been published on the effects of anesthetic drugs on LVDD 
since the early 1990s, when Pagel published his work describing the effects of inhaled 
anesthetics on LVDD in animal models using invasive catheter measurements.18,19,20 
Anesthesiologists are the gate-keepers of two important variables that affect loading 
conditions in the OR: fluids and drugs. Ongoing adjustments in fluid and drug therapy 
may have significant effects on underlying LVDD. 
Current anesthesia practice is to treat elderly patients with the same fluid 
management strategies as younger ones. Fluids are not set on a pump, but rather “free-
flowing” at the discretion of the provider. Are there optimal fluid and drug therapies that 
should be targeted for elderly patients with LVDD undergoing noncardiac surgeries, as it 
is known these patients are “high-risk,” even though it is “low-risk” surgery?21 Could 
noninvasive Doppler, as opposed to invasive catheter measurements, improve care? 
Can echocardiography be used to guide fluid and drug management during surgery 
LVDD patients? 
In the perioperative setting, using echocardiography to understand how 
elderly at-risk patients, with known preoperative evidence of LVDD, react to standard 
anesthesia management and surgical stimuli would be highly valuable and 
contribute to the limited body of knowledge on intraoperative diastolic dysfunction 
and management. Recent studies in goal-directed fluid management suggest that 
patients who receive fluids based on targeted left ventricular stroke volume (SV) 
measurements have improved outcomes compared to patients receiving liberal or 
“recipe” fluid management strategies. Several studies suggest that optimization of 




hospital stay.22,23,24 Intraoperative TEE can calculate left ventricular SV based on 
adjustments in fluids or drug therapy and may help define target therapy for patients 
with LVDD. 
Preliminary Studies 
The primary and secondary investigators completed a prospective, randomized, 
IRB-approved pilot study of 28 surgical subjects identified in pre-anesthesia clinic using 
TTE to have LVDD.25  Subjects were screened on the basis of age > 65 years or 
younger subjects with age-related cardiovascular phenotype. Average subject age was 
69.7 years (10 male, 18 female) and average body mass index (BMI) was 30.9 kg/m2.25 
Thirteen noncardiac surgeries were used for inclusion criteria, based on a previous study 
done by Hammil.3 Subjects were identified to have LVDD using assessment criteria 
based on guidelines from the ASE on the grading of LVDD.16 Subjects were randomized 
into two groups: a Standard HEmodynamic Management group (SHEM) versus an 
Echo-Guided HEmodynamic Management (EGHEM) group.  Subjects in the EGHEM 
group (n=14) received intraoperative TEE to manage fluids and optimize CO using left 
ventricular filling patterns. 
Preliminary Study Changes in LVDD 
It was noted in the EGHEM group that seven of 14 subjects (50%) had no 
change in LVDD grade intraoperatively while six (43%) had improvement in LVDD 
grade, and one subject (7%) worsened in LVDD grade. This led us to question the 
properties of diastolic indices, normally used to screen patients as a one-time 
measurement in awake, spontaneously breathing patients.  Our preliminary data 




supports the hypothesis that diastolic dysfunction is dynamic in the OR. This finding lent 
itself to investigate the dynamic nature of LVDD perioperatively. 
Preliminary Study Changes in Fluid Management  
One of the secondary aims of the preliminary study was to measure the 
difference in the frequency of congestive heart failure (CHF) and atrial fibrillation (A Fib) 
postoperatively between the two groups: subjects who underwent SHEM versus subjects 
who underwent EGHEM.  The incidence of CHF at 30 days was 21.4% in the SHEM 
group and 7% in the EGHEM group.  
The incidence of A Fib at 30 days 
was 28.6% in the SHEM group and 
14.3% in EGHEM group (Figure 1).25 
One statistically significant difference 
between the control and intervention 
group was the amount of 
intraoperative fluid administered 
based on the clinical algorithm. The 
EGHEM group received 12.7 
milliliters(mL)/kilogram(kg) of intraoperative intravenous fluid, while the SHEM group 
received 33.04 mL/kg (p=0.017).25 This led to the following question: what is the exact 
response of fluid to diastolic echocardiography indices and left ventricular CO? Does 
fluid administration improve or worsen either measurement?  This question led us to 
specifically determine if goal-directed echocardiography-guided hemodynamic 




Figure 1: Pilot Study. This graph demonstrates 
the finding of the pilot study where clinical 
outcomes at 30 days post op of CHF and A Fib 
showed a trend towards decrease in the 
interventional group (EGHEM) who received less 





Perioperative Fluid Management and LVDD 
It is understood that LVDD can lead to heart failure with preserved ejection 
fraction, often called HFpEF. While the clinical treatment of LVDD is unclear, the 
treatment of CHF, either systolic or diastolic, is aimed at decreasing afterload and 
preload with the goal of lowering left-sided filling pressures and promoting forward flow 
to improve organ perfusion. Optimizing fluid to minimize pulmonary congestion and 
peripheral edema is an important part of the treatment and avoidance of clinical heart 
failure. Utilization of diuretics is often the mainstay of therapy to prevent and or treat 
CHF. Specific clinical trials looking at the treatment of diastolic heart failure have 
included diuretics, beta-blockers, angiotensin converting enzyme inhibitors, drugs to 
control heart rate and prevent myocardial ischemia, and drugs to promote cardiac 
hypertrophy and remodeling such as phosphodiesterase-5 inhibitors and statins. The 
prevention of perioperative diastolic heart failure, however, has not been addressed in 
previous clinical trials. The question of what amount of intraoperative fluids should be 
given to patients that have LVDD undergoing surgery has not been addressed.  
In the last 10 years there has been a significant amount of literature looking at 
“restrictive” fluid therapy versus “liberal” fluid therapy versus “goal directed therapy” 
(GDT) in patients undergoing cardiac and noncardiac surgery. The majority of the 
literature in noncardiac surgical patients has been performed in major abdominal 
surgery. These studies performed in abdominal surgical cohorts have shown improved 
outcomes when GDT is used.22,23,24 Little is known on the effects of GDT in patients 





In 2015 the International Fluid Optimization Group published a consensus 
statement on perioperative fluid therapy recommendations.26 While the document points 
out that over or under hydration of perioperative patients is harmful, the most important 
analysis point to the fact that as clinicians, our ability to recognize and measure fluid 
sensitivity is often wrong. Previously perpetuated dogma of fluid therapy based on 
“nothing by mouth” (NPO) status, preoperative state, and the patient’s weight are 
unfounded and have little to no scientific evidence.26 At the same time, there is vast 
variability of fluid treatment and algorithms amongst institutions and practitioners, 
making research studies difficult.27,28,29 And what we have always learned as to exist as 
the “third space” has been abandoned.  
Arterial compliance (change in volume over a change in pressure) decreases as 
stiffness of the vasculature increases with aging. In patients with peripheral vascular 
disease, this is an added detriment to the patient’s ability to adapt to changes in vascular 
tone due to anesthetics. There are dynamic noninvasive measurements of “fluid 
responsiveness” that can be used in cases of hemodynamic instability to assess 
patient’s fluid status in the OR. These include pulse pressure variation, systolic pressure 
variation, and SV variation. If greater than 20% in patients on positive pressure 
ventilation, these may point to patients who are “fluid responders”. It is important to note 
that these 25% of patients under general anesthesia are in what is known as the “gray” 
zone”, between 8-15%.30 As such, these indirect measurement of fluid responsiveness 
may not be accurate or possible in a quarter of patients in the OR. 
A fluid bolus challenge, particularly using the passive leg raise test, may be the 
safest way to measure fluid responsiveness in patients that are undergoing surgery and 




boluses, such as 50-100cc, are also more recently being studied, as more and more 
literature points to over hydration with previously larger boluses (500mL or more) may be 
detrimental to patients who are undergoing surgery that are hemodynamically unstable. 
It is important to recognize that because a patient may be a fluid responder, it 
does not mean that fluid is necessary or needed. Low vascular tone, or low cardiac 
contractility may need to be addressed in order to improve ventricular filling.  
The recent consensus statement on perioperative fluid therapy recommended 
three things be present to safely administer fluids: the need for hemodynamic 
improvement, the presence of fluid responsiveness, and the lack of associated risk. 
Since fluid therapy in the elderly population with LVDD has not been studied, we do not 
know the associated risk of giving fluid to these patients. We know that elevated LV 
pressures are associated with poor outcomes, and that diastolic dysfunction is a 
precursor to diastolic heart failure, and that diastolic heart failure is treated with 
decreasing afterload and improving arterial compliance and decreasing LV filling 
pressures to improve coronary perfusion. We know the presence of LVDD increases 
perioperative mortality, and the treatment of HFpEF involves limiting fluid therapy and 
providing diuresis.1,2,3,4,5,31,32,33,34 The proposed research allowed us to begin to 
understand this risk by evaluating the relationship between LV filling pressures, left 
ventricular CO, and perioperative fluid management. 
Primary Study Objective and Hypothesis 
The primary objective of the study was to describe how moderate size fluid 
boluses changed CO in elderly vascular surgery patients with LVDD. Our secondary 
objective was to evaluate how moderate size fluid boluses change E/e’ in elderly patients 




III LVDD) or normal filling pressures with evidence of Grade I LVDD. We performed a 
prospective clinical trial to evaluate the effect of fluid boluses on intraoperative 
echocardiography diastolic measurements of LVDD including CO and E/e’ in elderly 
vascular surgical patients who have baseline LVDD. The clinical trial was a substudy of a 
larger NIH funded grant studying the effects of an echo-guided treatment algorithm on 
patients undergoing vascular surgery who had known LVDD (1R03 AG045103-01A1), 
Principle Investigator: Sasha K. Shillcutt, M.D. We used an echocardiography-driven 
algorithm to administer fluid boluses and measured both E/e’ and left ventricular CO 
intraoperatively on TEE during vascular surgery.  
Specific Aim 1 
To describe how moderate size fluid boluses change CO in patients with baseline 
elevated LV filling pressures (Grade II or Grade III LVDD). 
Specific Aim 2 
To describe how moderate size fluid boluses change E/e’ in elderly patients 
undergoing vascular surgery that have baseline elevated LV filling pressures (Grade II or Grade 
III LVDD) or normal filling pressures with evidence of Grade I LVDD. 
We assessed changes in LVDD in the subjects by administering a series of 250 mL fluid 
boluses prior to surgical incision on elderly patients undergoing vascular surgery. We then 





CHAPTER 2: METHODS 
Study Design  
The study was a controlled, single-blind prospective clinical trial in patients 
age 60 years or older with echocardiographic evidence of Grade I, II or III LVDD on 
preoperative TTE. All study protocols were approved by the Institutional Review 
Board at the University of Nebraska Medical Center.  
Study Population 
Study population included patients undergoing vascular surgery 60 years of age or 
older at the University of Nebraska Medical Center. Screening took place in the 
Preanesthesia Screening Clinic (PASC) outpatient clinic. The study population included 
both male and female patients age 60 years or older who had echocardiographic 
evidence of Grade I, II or III LVDD on preoperative TTE examination and met 
inclusion/exclusion criteria (Table 1). The subjects were undergoing any one of the 
vascular procedures listed below. 
1. Open abdominal aortic aneurysm (AAA) repair 
2. Endovascular aortic repair (EVAR) 








Inclusion and Exclusion Criteria  
The inclusion criteria and exclusion criteria of the study subjects are listed in Table 1 
below. 
Study Enrollment 
Potential study subjects were approached during their pre-surgical visit in the 
PASC by study investigators based on inclusion/exclusion criteria. Once informed 
consents were obtained, eligible patients underwent a screening TTE. Further enrollment 
into the study then required TTE evidence of LVDD based on echocardiography criteria 
Inclusion Criteria Exclusion Criteria Exclusion Justification 
Age 60 years and 
older 
Patients with 
expected hospital stay 
< 24 hours 
Inability to assess 
outcome measures 
Echocardiographic 
Evidence of Grade I, II 




undergo TEE and 
TTE 










1. Lower extremity 
bypass (LEB) 








or systemic sepsis 
Inability to properly 
consent patients 
Emergency operation Inability to properly 
consent patients 
American Society of 
Anesthesiologists Status 
V 
Inability to properly 
consent patients 
Participation in 
another clinical trial 
Interference with study findings 
4. Ability to read, 








for LVDD (see Figure 2). Subjects were then given a screening grade of LVDD (I, II or 
III) as described in Figure 2. The primary Grade of LVDD was given based on e’, then 
E/e’. While E/A ratio was considered as a secondary factor, LVDD Grade was assigned 
based on E/e’ only. 
 
Echocardiography Data Points 
The first TTE completed was considered the screening TTE in the PASC, and 
labeled as such. Immediately prior to induction of anesthesia and the day of planned 
surgery, another TTE was performed to collect diastolic indices listed in Table 2 and 
labeled as the baseline TTE. This baseline TTE was done the day of surgery to ensure 
that any differences in diastolic indices noted on intraoperative TEE when compared 
Figure 2: Preoperative Echocardiography Criteria and Grading of LVDD 
 
 
Figure 2: Preoperative Echocardiography Criteria and Grading of LVDD. 
e’ = lateral mitral annular tissue Doppler velocity, E = peak early mitral inflow velocity, A = 






to the screening TTE were less likely to be influenced by NPO status.  
 
Study Interventions 
After the induction of anesthesia and prior to surgical incision, a TEE probe was 
inserted into the subjects’ esophagus and a CX50 ultrasound machine with an S5-1 
sector array transducer probe or IE33 ultrasound machine using an X7-2t matrix array 
probe (Philips, Philips Healthcare, Andover, MA) was utilized for echocardiography data 
collection. Intraoperative TEE data points collected are listed in Table 2. The TEE probe 
was inserted per institutional research TEE protocol. Each subject was analyzed for two 
main measurements: Doppler derived left ventricular end diastolic pressure (E/e’) and 
Table 2: Echocardiography Data Points Collected during Screening TTE, Baseline 






 Left Ventricular Wall 
 
Parasternal SAX Assessed by TTE only 




Apical 4C, 2C, LAX, 
Parasternal SAX 
ME 4C, 2C, LAX, 
Transgastric SAX 
Pulmonary Vein Flow Apical 4C ME 2C 
E velocity, Deceleration 
   
Apical 4C ME 4C 
e' Lateral mitral annulus, 
averaged over 3 beats, 
Apical 4C 
Lateral mitral annulus, 
averaged over 3 beats, 
ME 4C 
LVOT diameter Parasternal LAX ME AV LAX 
LVOT VTI (for Stroke 
Volume) 
Apical LAX Deep gastric LAX 
 
Table 2: Echocardiography data points and their corresponding windows/views for 
both the TTE and TEE examinations performed.  
AV = Aortic Valve; C = Chamber; e’ = lateral mitral annular tissue Doppler velocity, 
LAX = Long Axis View; ME = Midesophageal; SAX = Short Axis View VTI = 
velocity time integral, LVOT = Left ventricular Outflow Tract, E velocity = Peak 




SV/CO using Doppler-derived velocity time integral (VTI) and left ventricular outflow tract 
(LVOT) diameter.  
The E/e’ was derived by using the E velocity obtained in the Midesophageal 
4 Chamber view (ME 4C) and the e’ velocity obtained at the lateral mitral valve 
annulus also in the ME 4C view. Left ventricular CO was calculated by using the 
following equations: πr2 x LVOT VTI x Heart Rate = left ventricular CO where VTI = 
the left ventricular VTI and r = LVOT diameter/2. Those values were entered into an 
electronic data collection form as T0 (Time zero) Intraoperative TEE. 
Interventions and Duration  
After initial measurements of CO and E/e’ were taken, a 250 mL bolus of 
normal saline (NS) was administered to the subject via a peripheral intravenous 
catheter for subjects who had normal Grade LVDD, Grade I LVDD, or Grade II 
LVDD. Subjects with Grade III LVDD were not transfused the bolus of fluid due to 
risk of pulmonary edema.  After the first bolus was complete, repeat measurements 
of CO and E/e’ were taken and documented into the electronic database. It is 
important to note that while we did not have any patients on screening TEE who 
had normal LVDD Grade (Grade 0), we had to include Grade 0 in the clinical 
algorithm, as some subjects theoretically could have a change in LVDD Grade from 
Grade I to Grade 0 during the perioperative period (as seen in a change from Grade 
I on screening TTE, for example, to Grade O on the Preoperative TTE), as 
evidenced by our pilot study. 
 A clinical fluid algorithm was then used based on the subject’s change in 
CO to the initial 250 mL bolus seen in Figure 3. If after one 250 mL bolus there was 




or if the CO decrease with fluid bolus administration then no more fluid boluses 
were given.  
After the second 250 mL bolus of NS repeat CO and E/e’ measurements 
were assessed. If after the second 250 mL bolus there an increase in CO, a third 
and final 250 mL bolus was administered and both CO and E/e’ measured and 




Figure 3: Intraoperative Fluid Bolus Algorithm  
 
 
Figure 3: Algorithm for fluid bolus of 250 mL normal saline (NS) and response of cardiac 
output.  






Data Collection  
Patient demographics, comorbidities, surgical status and TTE/TEE examination 
data was collected and placed into an electronic database with the corresponding time 
interval in which the data was collected. Hemodynamic measurements (blood pressure, 
pulse, pulse oximeter) were automatically placed into the EMR from the hemodynamic 
monitor intraoperatively for any further analysis, as were all drugs administered 
intraoperatively.  
Clinical Endpoints 
The clinical end points measured are listed below in Table 3. While the 
intervention was driven on the change in left ventricular CO from fluid bolus, early (E) 
and late (A) mitral inflow peak velocities, pulmonary vein flow patterns of systolic or 
diastolic dominance, E/e’, and left ventricular ejection fraction were also measured as 
seen in Table 3. 






Surgical Procedure  
Endpoint Measurement 
Left Ventricular Cardiac Output πr2 x LVOT VTI x Heart Rate 
Peak Early Mitral Inflow Velocity E 
Peak Late Mitral Inflow Velocity A 
Pulmonary Vein Flow Pattern Systolic or Diastolic Dominant 
Left Ventricular Ejection Fraction EF% by biplane method 
Lateral Mitral Annular Tissue Doppler Velocity e’ 
LVDD Grade  0, I, II, III 
Table 3 




Data Collected Per Time Period 
LVDD Grade, LV CO and E/e’ were collected at six different time periods as 
listed in Figure 4: 
Figure 4. Timeline of echocardiography data points.  
TTE=transthoracic echocardiography, TEE=transesophageal echocardiography 
• Screening TTE (performed in PASC) 
• Baseline TTE (performed day of surgery, prior to induction) 
• T0 TEE (performed after induction of anesthesia, prior to incision) 
• TEE Bolus 1 (performed after first 250 mL NS bolus) 
• TEE Bolus 2 (performed after first 250 mL NS bolus) 
• TEE Bolus 3 (performed after first 250 mL NS bolus) 
Statistical Considerations  
 Descriptive statistics were used to describe patient demographics and changes 
within LVDD grade. Counts, percentages were used for categorical data and means and 
standard deviations for continuous data. Side by side box plots were used to show the 
distribution of LVDD grade, CO, and E/e’.   
 
 










CHAPTER 3: RESULTS  
Seventeen subjects were identified in the PASC that met study criteria and 
enrolled in the study. One subject voluntarily withdrew from the study during the 
Preoperative TTE leaving a total number of subjects enrolled=16. 
Baseline Characteristics 
The average subject age was 74 years. There were 12 (75%) males and 4 
females (25%). Average BMI was 26 kg/m2. Table 4 lists the subject characteristics, 
cardiac risk factors and comorbidities. The surgical procedure type is also listed in Table 
4.  
Table 4: Subject Characteristics, Comorbidities and Surgical Procedure Type 
 Study Subjects (N=16) 
[n (%)] or [Mean (SD)] 
Subject Demographics  
• Male Sex 12 (75%) 
• Age (years) 74.0 (7.7)  
• BMI (kg/m2) 26 (7.0) 
• Race   
Caucasian 15 (94%) 
African American 1 (6%) 
 
Cardiac Risk/Comorbidities   
• Hypertension 13 (81%) 
• Peripheral Vascular Disease 9 (56%) 
• CAD 7 (44%) 
• COPD 7 (44%) 
• Chronic Kidney Disease 7 (44%) 
• Diabetes Mellitus 4 (25%) 
• Cerebral Vascular Accident 2 (13%) 
 
Surgical Procedure Type  
• Open AAA Repair 4 (25%) 
• EVAR 5 (31%) 
• LE Bypass/Repair/Stent 7 (44%) 
Table 4: Subject demographics, risk factors and comorbidities and surgical procedure of 
the N=16 subjects.  
AAA=abdominal aortic aneurysm, BMI=body mass index, CAD=coronary artery disease 
COPD=chronic obstructive pulmonary disease, EVAR=endovascular aortic repair, 





Preoperative Screening TTE Examination  
The Preoperative Screening TTE data collected and Grade of LVDD is listed in 
Table 5. All subjects were found to have evidence of LVDD (Grade I, II) on screening 
TTE examination. Ten (63%) subjects had Grade I, while six subjects had Grade II 
(37%). None of the subjects had evidence of LVDD Grade III on screening TTE. 
 
Day of Surgery Baseline TTE Examination  
 The Preoperative Baseline TTE data collected and Grade of LVDD is listed in 
Table 6. Fifteen of the 16 subjects were found to have LVDD Grade I [N=12 (75%)] or 
Grade II [N=3 (19%)] on the preoperative baseline TTE examination the day of surgery. 
On one of the subjects changed to LVDD Grade I from Grade II on the screening TTE 
while one subject when from Grade I to normal left ventricular diastolic function the day 
of surgery when compared to the screening PASC TTE.  
Table 5: Preoperative Screening TTE Data, N=16 
Screening TTE Data  N=16 [n (%)] or [Mean (SD)] 
Left Ventricular Ejection Fraction (%) 51 (8.04) 
Left Ventricular Cardiac Output (L/min) 5.2 (1.7)  
e’ 8.3 (2.7) 
E/e’  10.2 (3.1) 
Preoperative Screening Grade of LVDD  
• LVDD Grade I 10 (63%) 
• LVDD Grade II 6 (37%) 
• LVDD Grade III - 
Table 5: Preoperative screening data from the PASC screening TTE examination. 
TTE=transthoracic echocardiogram, E= peak early mitral inflow velocity. e’=lateral mitral 







 All subjects underwent general anesthesia technique with intravenous induction 
and maintenance of anesthesia with vapors and narcotics. Saline intravenous flushes in 
10 mL syringes were used to push anesthetic drugs for induction to minimize “free-flow” 
fluid administration. Drugs utilized in study subjects for induction and anesthetic 
maintenance are listed in Table 7.  
Intraoperative TEE Examination (T0) 
Table 6: Preoperative Day of Surgery Baseline TTE Data (N=16) 
Baseline TTE Data  N=16 [n (%)] or [Mean (SD)] 
Left Ventricular Ejection Fraction (%) 52.5 (5.2) 
Left Ventricular Cardiac Output (L/min) 5.1 (2.2) 
e’ 8.5 (2.3) 
E/e’  9.9 (3.3) 
Preoperative Screening Grade of LVDD  
• LVDD Normal (Grade 0) 1 (6%) 
• LVDD Grade I 12 (75%) 
• LVDD Grade II 3 (19%) 
• LVDD Grade III - 
Table 6: Preoperative Baseline data from the Day of Surgery baseline TTE examination.  
TTE=transthoracic echocardiogram, E= Peak Early Mitral Inflow Velocity. e’=Lateral Mitral 
Annular Tissue Doppler Velocity, L/min=liters/minute, LVDD=left ventricular diastolic 
dysfunction 
Table 7: Anesthetic Drugs Utilized in Study (N=16) 
Anesthetic Drug Utilized N=16 
propofol 16 (100%) 
fentanyl 15 (94%) 
midazolam 13 (81%) 
cisatricurium 13 (81%) 
sevoflorane 12 (75%) 
desflurane 4 (25%) 
sufentanil 4 (25%) 
rocuronium 3 (19%) 




 The Intraoperative TEE data collected performed at T0 (after induction of 
anesthesia and prior to fluid intervention administration) is listed in Table 8. On initial 
intraoperative TEE (T0) 10 subjects had Grade I, four subjects had Grade II, and two 
subjects had changed to LVDD Grade 0, or had normal appearing diastolic function. No 
subjects at T0 had LVDD Grade III.  
 
Primary Outcome Data  
For the entire subject cohort (N=16), the overall CO decreased after Bolus 1 (250 
mL) from 4.9 L/min to 4.6 L/min. Nine subjects (9/16, 56%) had no change or a decrease 
in CO with Bolus 1. Seven subjects (7/16, 44%) had an increase in CO with Bolus 1 and 
underwent Bolus 2 (250 mL). After Bolus 2, two subjects (N=2/7, 29%) had an increase 
in CO. A side-by-side boxplot showing the distribution of CO at each of the six time 
Table 8: Intraoperative TEE Data T0 (N=16) 












Left Ventricular Ejection Fraction (%) 53 (7.2) - - - 
Left Ventricular Cardiac Output (L/min) 4.9 (2.0) 4.6 (1.6) 4.6 (1.5) 5.0 (0.5) 
e’ 8.8 (2.6) 9.4 (3.1)  8.9 (2.5) 8.0 (2.8) 
E/e’  8.7 (4.5) 8.2 (3.9) 7.8 (2.3) 8.5 (2.4) 
Preoperative Screening Grade of LVDD     
• LVDD Grade 0 (Normal) 2 1 - - 
• LVDD Grade I 10 9 4 2 
• LVDD Grade II 4 6 2 - 
• LVDD Grade III -  1 - 
Table 8: Intraoperative TEE Data T0 collected after induction of anesthesia and prior to 
fluid bolus intervention. After each 250mL bolus of NS, cardiac output and E/e’ were 
calculated and their values recorded per clinical algorithm listed in Figure 3. 
TTE=transthoracic echocardiogram, E= Peak Early Mitral Inflow Velocity. e’=Lateral Mitral 





periods (Screening TTE, Baseline TTE, T0 TEE, TEE Bolus 1, TEE Bolus 2, and TEE 
Bolus 3) is noted below in Figure 5.  
Individual patient plots of CO, over each time period, are listed in Figure 6. 
Trends at each time period are shown. 
 
 
Figure 5: Left Ventricular Cardiac Output Distribution at Each Time Period 
 
Figure 5: Box Plot depicting the distribution of LV CO at each time period. All subjects (N=16) 
received the 1st bolus of 250 mL of NS, and then had TEE Bolus 1 data collected. Seven subjects 
received a 2nd bolus of 250 mL, while only 2 subjects had the 3rd bolus and TEE data collected. 
N=subject number, TEE= transesophageal echocardiography, TTE=transthoracic 











Figure 6: Individual patient’s Cardiac Output at each time period.   
CO=cardiac output, mL = milliliters, TEE= transesophageal echocardiography, TTE=transthoracic 





















Cardiac Output (mL) Per Patient by Time Period
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Patient 7 Patient 8 Patient 9 Patient 10 Patient 11 Patient 12




Secondary Outcome Data  
A side-by-side boxplots showing the distribution of E/e’ at each of the six time 
periods (Screening TTE, Baseline TTE, T0 TEE, TEE Bolus 1, TEE Bolus 2, and TEE 
Bolus 3) is listed below in Figure 7. The E/e’ decreased from 8.7 to 8.2, while e’ 
increased from 8.8 to 9.5. 
 
 
Figure 7: Left Ventricular E/e’ Distribution at Each Time Period 
 
Figure 7: Box Plot depicting the distribution of E/e’ at each time period. All subjects 
(N=16) received the 1st bolus of 250 mL of NS, and then had TEE Bolus 1 data collected. 
Seven subjects received a 2nd bolus of 250 mL, while only 2 subjects had the 3rd bolus 
and TEE data collected. 
N=subject number, TEE= transesophageal echocardiography, TTE=transthoracic 






Figure 8 displays Individual patient plots of E/e’ over each time period. Trends at each 
time period are shown. 





Figure 8: Individual patient’s E/e’ at each time period.   













Screening TTE Baseline TTE T0 TTE Bolus 1 Bolus 2 Bolus 3
E/
e-
E/e' Per Patient by Time Period
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Patient 7 Patient 8 Patient 9 Patient 10 Patient 11 Patient 12




Changes in LVDD Grade 
The frequency distribution of LVDD Grade at the six time periods (Screening 
TTE, Baseline TTE, T0 TEE, TEE Bolus 1, TEE Bolus 2, and TEE Bolus 3) is displayed 
below in a clustered bar chart in Figure 9. Five (N=5/16, 31%) subjects had a changes in 
LVDD Grade after the first bolus.  
Figure 9: Left Ventricle Diastolic Dysfunction Grade Distribution at Each Time 
Period 
 
Figure 9: Box Plot depicting the distribution of LVDD Grade at each time period. All 
subjects (N=16) received the 1st bolus of 250 mL of NS, and then had TEE Bolus 1 data 
collected. Seven subjects received a 2nd bolus of 250 mL, while only 2 subjects had the 
3rd bolus and TEE data collected. 
N=subject number, TEE= transesophageal echocardiography, TTE=transthoracic 








Seven subjects had an improvement in CO after the first bolus, and hence then 
received a second bolus per protocol. The seven subjects who had an improvement in 
CO, the majority of them (N=5/7,97%) were LVDD Grade I. Two of the subjects were 
Grade II.  
Of those seven subjects, two (N=2/7, 29%) had a change in LVDD Grade after 
the second bolus. Both of the subjects had an increase in LVDD (one subjects changed 
from LVDD Grade I to II, while the other went from Grade II to Grade III. Two subjects 
had an improvement in CO, and received a third bolus of 250 mL NS. One of the two of 
subjects (N=1/2) changed his/her LVDD Grade from Grade II to Grade I. 
Safety Data 
 There were no adverse events reported with TEE probe insertion or removal or 
the performance of the TEE. There were no incidences of difficult probe placement or 
withdrawal. The subjects’ medical record was reviewed at hospital discharge and there 




CHAPTER 4: DISCUSSION 
The primary aim of this study was to evaluate the effect of fluid administration on 
left ventricular CO in surgical patients with evidence of LVDD. LVDD is risk factor for 
diastolic heart failure, and perioperative risk is increased for events such CHF and 
myocardial infarction in patients that have often asymptomatic LVDD.7 The direct effects 
of fluid administration during vascular surgery have not been studied in this population. 
This study found that in the majority of 16 vascular surgical subjects with LVDD, the 
administration of fluid boluses did not increase left ventricular CO. 
While the administration of fluids is contraindicated in patients that have clinical 
heart failure, and preclinical evidence of LVDD is a risk for heart failure, perioperatively 
fluid administration to surgical patients is often warranted due to surgical blood loss, 
shifts in fluid, and insensible losses. Guidelines and expert recommendations on how to 
approach fluid administration during the perioperative period for patients that have LVDD 
are lacking. As such, this study sought to evaluate the effects of fluid in patients with 
LVDD undergoing vascular surgery with real-time hemodynamic indices such as Doppler 
derived CO and also left ventricular end-diastolic pressure derived from Doppler 
echocardiography.  
We saw that in 16 elderly surgical subjects with LVDD, there was a trend that 
250 mL fluid boluses did not increase CO in nine of 16 of patients.  In patients who did 
have a rise in CO with the fluid bolus, they were more likely to have LVDD Grade I and 
normal Doppler-derived left-sided filling pressures.  This would support idea that in 
patients with LVDD Grade I, LV filling pressures are likely normal, and the risk of 
developing CHF or diastolic heart failure may be lower than in patients with higher grade 




administration of perioperative fluids may be less likely to cause postoperative adverse 
events such as heart failure. Preoperative screening of patients and classification of 
LVDD Grade may provide information to guide anesthesiologists on perioperative fluid 
administration decisions. In the perioperative arena, where fluid boluses are often 
required and necessary, some patients with LVDD Grade I may respond to fluid 
challenges with an improvement in LV CO as suggested by this pilot data. Whereas 
patients that have advanced stages of LVDD, such as LVDD Grade II or III, may not see 
this benefit. As such, the risk/benefit analysis of fluid administration to this population 
needs to be analyzed with future outcome studies. 
The second aim of the study was to evaluate if and how fluid boluses changed 
E/e’, or Doppler-derived filing pressures, in subjects with LVDD Grade II and Grade III. 
We saw a trend that moderate fluid boluses did not change E/e’, they may change LVDD 
Grades. For example, after the first 250mL bolus, we found 4 subjects (N=4/16, 25%) 
demonstrated an increase in their LVDD Grade, suggesting an increase in LV filling 
pressures. This was also demonstrated in two subjects (N=2/7, 29%) who qualified for a 
second fluid bolus of 250mL. While 5 subjects demonstrated no change in LVDD Grade, 
two subjects demonstrated a worsening LVDD Grade. While this section of the study 
was not powered to evaluate clinical outcomes, previous studies have demonstrated that 
patients with worsening LVDD Grade have worse clinical outcomes.4,7,8 A further study 
evaluating the change in subjects LVDD grade that is powered to demonstrate a 
correlation with an increase in adverse outcomes is currently underway. 
This second aim provides more insight into the direct effects of fluid 
administration to two often coupled indices: E/e’, or Doppler-derived LV filling pressure 




proportional, whereas and increase in E/e’ theoretically leads to an increase in LVDD 
Grade, there seems to be more to this relationship than a pure linear association. As 
E/e’ is a continuous variable versus LVDD Grade being categorical (0, I, II, III), it can be 
extrapolated that there will be changes in LVDD Grade, which has been historically 
derived from mitral inflow velocity patterns and pulmonary vein flow velocity patterns 
which may or may not be reflected in E/e’, which is derived from both mitral inflow 
velocity and tissue-Doppler velocity. The fact that fluid boluses were found to result in a 
worsening of LVDD Grade in some subjects but did not result in a significant change in 
E/e’ suggests that these indices may reflect different physiological changes. The 
differences in response to fluid boluses between these two indices may be better 
explained by the effect of the loading conditions, whereas mitral inflow velocities and 
pulmonary vein flow velocities are more load-dependent, where e’ is well understood to 
be less dependent on loading conditions.5,16 Which of these indices do in fact change 
more with fluid administration, and whether those changes are tied to differences in 
clinical outcomes, is part of the adjunct clinical trial underway. 
The findings in this study, similar to our preliminary study, demonstrate the 
dynamic and sensitive nature of LVDD Grade.25 The Grade of LVDD, which has been 
traditionally determined by mitral inflow patterns and pulmonary vein flow patterns and 
tissue Doppler velocity of the mitral annulus, can change with loading conditions during 
the perioperative period, as shown in our pilot study and repeated in this study. The fact 
that LVDD Grade can change with fluid administration begs one to wonder if 
anesthesiologists who administer perioperative fluids to high-risk patients can optimize 
fluid administration, resulting in optimizing LVDD Grade and LV CO. And if 
anesthesiologists can optimization fluids based on a patient’s baseline LVDD Grade, 




Vascular surgical patients, most of which are elderly, present a special set of 
challenges to the anesthesiologist. Risk factors such as hypertension, advanced age, 
coronary artery disease (CAD), and renal dysfunction are common in the vascular 
surgical population. Arterial hypertension and higher baseline perfusion pressures, along 
with reperfusion injury associated with the cross-clamping and release of major 
vasculature during surgery make it very challenging for the anesthesiologist to maintain 
adequate organ perfusion and avoid post-operative organ failure.35 Optimizing fluid 
management is very important to perioperative organ perfusion.36 The disruption of the 
capillary barrier, from either hypovolemia or hypervolemia, is associated with poor 
outcomes, leading to current investigations to suggest GDT may lead to improved 
postoperative outcomes in major surgery.36,37  
GDT, targeted at providing euvolemia and avoidance of excess salt and water, 
plays an important part of improving outcomes in major surgery and in high risk patients, 
who often have a hard time excreting water and/or salt due to comorbidities. But what is 
GDT in patients with LVDD? This study adds to the first step in defining GDT in this 
population. 
The previous mantra of “filling the third space” has been disbanded as this space 
does not exist physiologically.35, 36,37,38 However, for the last century, the doctrine of filling 
the third space, a “hidden” area within the body thought to consume volume in 
perioperative patients, has been perpetuated from generation to generation of 
physicians. Despite our recent knowledge that this space does not exist, trends in fluid 
administration illustrate that many clinicians still practice liberal fluid practices based on 
this theory, institutional preferences, and surgical tendencies.27  Intraoperative insensible 




mg/kg/hour, are now known to be much lower, and 0.5-1 mg/kg/hour is the accepted 
replacement therapy to avoid capillary leak and interstitial edema.35,36,37 In order to 
optimize fluid management, GDT has recently been adopted, where fluid administration 
is based on physiological needs and hemodynamic data such as SV. While GDT has 
been shown to be beneficial in many surgical arenas, it is not practiced in most 
institutions. The institution of GDT into perioperative practice has been limited due 
requirements of a focused evaluation of hemodynamic measurements such as SV or 
CO, which many institutions lack the resources to fulfill. Current studies in major 
abdominal surgery have shown that fluid protocols and algorithms supporting GDT are 
associated with improved outcomes.36,39 Recent meta-analyses and reviews suggest it is 
not the type or amount of fluid that is most important, but rather following a protocol 
based on hemodynamic data.39   
SV is considered to be the gold standard for measuring a patient’s response to 
fluid and where the patient is on the Frank-Starling curve.30,36,40 Once a patient is 
euvolemic, administration of fluid will result in a <10% change in SV and assumed to be 
on the plateau of the Frank-Starling curve.41  While GDT using SV is invaluable, it 
requires training and expertise not available to all patients. While not every patient 
undergoing vascular surgery may have GDT using SV, the establishment of guidelines 
and recommendations to optimize fluid management for this population may be 
beneficial to shift the current paradigms. As this study revealed, changes in LVEDP and 
SV/CO with fluid boluses may not be as predictable in the patients with LVDD. Vascular 
surgery, unlike major abdominal surgery, has its own set of challenges for euvolemia 





Can perioperative fluid algorithms optimize hemodynamics and outcomes in 
patients with LVDD undergoing vascular surgery? The answer to this question has not 
been studied. While general preventative practices to avoid diastolic heart failure in 
patients with LVDD exist, we do not know how to avoid diastolic heart failure in surgical 
patients with LVDD, many of which undergo vascular surgery. This study is the first 
study to measure SV and CO response to fluid boluses in high-risk patient undergoing 
vascular surgery. While heart rate and mean arterial pressure are the traditional 
mainstay of clinicians to determine response to fluid, they are poor estimates of true 
circulating blood volume and hypovolemia. A meta-analysis by Marik and colleagues 
found that only 50% of patients who are hemodynamically unstable are fluid 
responders.41 In vascular surgical patients, fluid optimization is critical. Clamping and 
unclamping of the aorta and major vessels, reperfusion of organs, potential for 
hemorrhage, and protection of organs require significant fluid management during the 
surgical period. High risk patients with vascular disease and cardiac comorbidities 
require a focused approach to fluid optimization during vascular surgery, where diseases 
such as LVDD can complicate fluid requirements. Understanding the patient’s 
physiological response to fluids and the risk associated with under or over hydration is 
arguably one of the most difficult yet important tasks to the anesthesiologist. 
Understanding how left ventricular filling pressure and SV change in response to over 
and under hydration is the first step to defining this important task. 
Future studies are warranted to assess the need for GDT, how GDT is defined, 
and how and if GDT changes outcomes in vascular surgical patients. Anesthesiologists 
are the gatekeepers of perioperative fluid management. Dissemination of target goals 
and the definition of GDT to promote enhanced recovery after vascular surgery are 
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ADULT CONSENT - CLINICAL BIOMEDICAL 
Title of this Research Study 
Echocardiography-Guided Hemodynamic Management Strategy to Improve 
Clinical Outcomes for Elderly Patients with Left Ventricular Diastolic Dysfunction 
Undergoing Noncardiac Surgery 
 
Invitation 
You are invited to take part in this research study. You have a copy of the 
following, which is meant to help you decide whether or not to take part: 
• Informed consent form 
• "What Do I need to Know Before Being in a Research Study?"  
• The Rights of Research Subjects 
 
Why are you being asked to be in this research study? 
You are being asked to be in this research study because you are scheduled 
to undergo a major non-heart surgery at the University of Nebraska Medical Center, 
and you are 60 years of age or older. 
 
A total of 200 patients will be enrolled in the study. 
 
What is the reason for doing this research study? 
The purpose of this research is to see if echocardiography (a sound wave picture 
of the heart) during surgery can help the doctor who gives the sedation 
medication (Anesthesiologist) better manage fluid levels and medications during the 
surgery, and reduce the chance of complications during and after the surgery 
 
What will be done during this research study? 
You will be randomly assigned (like the flip of a coin) to one of two groups 
before your surgery. An equal number of patients will be assigned to each 
research group. Subjects who do not have stiffening of the large chamber located 
on the left side of the heart (Left Ventricular Dysfunction) also known as LVDD, 
seen on echocardiogram completed prior to surgery, will be withdrawn from the 
study. 
 
All subjects will have an echocardiogram before surgery. This involves placing 
a probe on your chest and taking sound wave pictures of your heart through 
your chest. After you are asleep for the surgery, you will have a different 
echocardiogram probe placed through your mouth into your esophagus, by the 
anesthesia doctor. This will take sound wave pictures of your heart during the 
entire operation. The probe will be removed before you wake up. 
 
If you are in the EXPERIMENTAL group,the anesthesia doctor will adjust how 
he gives you IV fluids, or blood pressure medicines, based on the measurements 
from the pictures of your heart from the echocardiogram. 
 
If you are in the STANDARD group, you will be treated as if you weren't in 
the research. The IV fluids or blood pressure medicines you get during the 
operation will be based on the anesthesia doctor's judgment, based on your 
heart rate, blood pressure and physical examination. 
All subjects will have data collected including: clinical outcomes (heart failure, 
atrial fibrillation, arrhythmia, or other cardiac complications), blood draws, length 
of stay (hospital or Intensive Care Unit), readmission to the Hospital for a 
cardiac event (heart attack, A-fib, congestive heart failure, or death) at 30 or 90 
days, new diagnosis of Acute Kidney Injury. All data will be collected from your 
medical record; however, if no records are available, you may receive a phone call to 
ensure that you have not been treated at a hospital other than UNMC. If you are 
treated within 30 days of your surgery, outside of UNMC, the study team will have 
your permission to collect those medical records 
 
What are the possible risks of being in this research study? 
The risks associated with the Echocardiography Guided Hemodynamic 
Mangement (EGHEM) study can be related to direct injury or trauma from the 
probe that goes down your throat to look at your heart (transesophageal 
echocardiography (TEE)) probe, or from mismanagement of fluid and/or drug 
administration during surgery. The risks from direct TEE probe trauma include 
damage or tears to the throat, water being pushed in to the lungs and dental 
trauma. The risks from mismanagement of fluid and/or drug administration include 
acute heart attacks, abnormal fluid build-up in the lungs, kidney failure, orthostatic 
hypotension (low blood pressure when changing position)and/or death. 
 
It is possible that other rare side effects could occur which are not described in 
this consent form. It is also possible that you could have a side effect that 
has not occurred before. 
 
What are the possible benefits to you? 
You may benefit if you are randomized to the experimental group, and the 
experimental group is found to be better than the standard group, which may 
reduce your post-operative complications association with your heart. However, you 
may not get any benefit from being in this research study. 
 
What are the possible benefits to other people? 
Possible benefits to society are an advancement in medical knowledge in the 
management of future patients with heart disease during major surgery. 
 
What are the alternatives to being in this research study? 
Instead of being in this research study, you can choose not to participate. 
 
What will being in this research study cost you? 
There is no cost to you to be in this research study. 
 
Will you be paid for being in this research study? 
You will not be paid to be in this research study. 
 
Who is paying for this research? 
This research is being paid for by grant funds from the National Institute of 
Health (NIH) and the American Society of Geriatrics. UNMC/TNMC receives money 
from the NIH to conduct this study. 
 
What should you do if you are injured or have a medical problem during this 
research study? 
Your welfare is the main concern of every member of the research team. If you 
are injured or have a medical problem as a direct result of being in this study, you 
should immediately contact one of the people listed at the end of this consent form. 
Emergency medical treatment for this injury or problem will be available at the 
Nebraska Medical Center. If there is not sufficient time, you should seek care from 
a local health care provider. 
 
UNMC/TNMC has no plans to pay for any required treatment or provide other 
compensation. If you have insurance, your insurance company may or may not 
pay the costs of medical treatment. If you do not have insurance, or if your 
insurance company refuses to pay, you will be expected to pay for the medical 
treatment. 
 
Agreeing to this does not mean you have given up any of your legal rights. 
 
How will information about you be protected? 
You have rights regarding the protection and privacy of your medical 
information collected before and during this research. This medical information is 
called "protected health information" (PHI). PHI used in this study may include your 
medical record number, address, birth date, medical history, the results of 
physical exams, blood tests, x-rays as well as the results of other diagnostic 
medical or research procedures. Only the minimum amount of PHI will be collected 
for this research. Your 
research and medical records will be maintained in a secure manner. 
 
Who will have access to information about you? 
By signing this consent form, you are allowing the research team to have access 
to your PHI. The research team includes the investigators listed on this consent 
form and other personnel involved in this specific study at the Institution. 
 
Your PHI will be used only for the purpose(s) described in the section What is 
the reason for doing this research study? 
 
You are also allowing the research team to share your PHI, as necessary, with 
other people or groups listed below: 
The UNMC Institutional Review Board (IRB) Institutional officials designated by the 
UNMC IRB 
Federal law requires that your information may be shared with these groups: The 
HHS Office for Human Research Protections (OHRP) 
National Institutes of Health (NIH) 
You are authorizing us to use and disclose your PHI for as long as the 
research study is being conducted. 
 
You may cancel your authorization for further collection of PHI for use in this 
research at any time by contacting the principal investigator in writing. However, 
the PHI which is included in the research data obtained to date may still be used. If 
you cancel this authorization, you will no longer be able to participate in this 
research. 
 
How will results of the research be made available to you during and after the 
study is finished? 
In most cases, the results of the research can be made available to you when 
the study is completed, and all the results are analyzed by the investigator or the 
sponsor of the research. The information from this study may be published in 
scientific journals or presented at scientific meetings, but your identity will be 
kept strictly confidential. 
 
If you want the results of the study, contact the Principal Investigator at the 
phone number given at the end of this form or by writing to the Principal 
Investigator at the following address: 
Sasha K Shillcutt, MD 
 
University of Nebraska Medical Center 
981145 Nebraska Medical Center Omaha, NE 68198-1145 
 
A description of this clinical trial will be available on www.ClinicalTrials.gov, as 
required by U.S. law. This website will not include information that can identify you. 
At most, the website will include a summary of the results. You can search this 
website at any time. 
 
What will happen if you decide not to be in this research study? 
You can decide not to be in this research study. Deciding not to be in this 
research will not affect your medical care or your relationship with the investigator 
or UNMC/TNMC. Your doctor will still take care of you and you will not lose any 
benefits to which you are entitled. 
 
What will happen if you decide to stop participating once you start? 
You can stop participating in this research (withdraw) at any time by contacting 
the Principal Investigator or the Lead Coordinator by phone, or you may also contact 
one of these individuals in writing at the following address: 
 
Sasha K Shillcutt, MD 
 
University of Nebraska Medical Center 981145 Nebraska Medical Center Omaha, NE 
68198-1145 
Deciding to withdraw will otherwise not affect your care or your relationship with 
the investigator or UNMC/TNMC. You will not lose any benefits to which you are 
entitled. 
 
For your safety, please talk to the research team before you stop taking any 
study drugs or stop other related procedures. They will advise you how to withdraw 
safely. If you withdraw you may be asked to undergo some additional tests. You 
do NOT have to agree to do these tests. 
 
Any research data obtained to date may still be used in the research. 
 
Will you be given any important information during the study? 
You will be informed promptly if the research team gets any new information 
during this research study that may affect whether you would want to continue 
being in the study. 
 
What should you do if you have any questions about the study? 
You have been  given a copy of "What Do I Need to Know Before Being in a 
Research Study?" If you have any questions at any time about this study, you 
should contact the Principal Investigator or any of the study personnel listed on this 
consent form or any other documents that you have been given. 
 
What are your rights as a research participant? 
You have rights as a research subject. These rights have been explained in 
this consent form and in The Rights of Research Subjects that you have been 
given. If you have any questions concerning your rights or complaints about the 
research, you can contact any of the following: 
The investigator or other study personnel Institutional Review Board (IRB) 
Telephone: (402) 559-6463 Email: IRBORA@unmc.edu 
Mail: UNMC Institutional Review Board, 987830 Nebraska Medical Center, Omaha, 
NE 68198-7830 
Research Subject Advocate Telephone: (402) 559-6941 Email: unmcrsa@unmc.edu 
 
Documentation of informed consent 
You are freely making a decision whether to be in this research study. Signing 
this form means that: 
You have read and understood this consent form. You have had the consent form 
explained to you. 
You have been given a copy of The Rights of Research Subjects You have had your 
questions answered. 
You have decided to be in the research study. 
If you have any questions during the study, you have been directed to talk to one of 
the investigators listed below on this consent form. 
You will be given a signed and dated copy of this consent form to keep. 
 
 
Signature of Subject    Date    
My signature certifies that all the elements of informed consent described on 
this consent form have been explained fully to the subject. In my judgment, the 
subject possesses the legal capacity to give informed consent to participate in this 
research and is voluntarily and knowingly giving informed consent to participate. 
 
Signature of Person obtaining consent                        
Date    
 
Authorized Study Personnel Principal 
Shillcutt, Sasha phone: 402-559-3685 










Duhachek-Stapelman, Amy phone: 402-559-4081 







Schulte, Thomas phone: 402-559-4081 










Goergen, Katie phone: 402-559-4081 








Markin, Nicholas (Nick) phone: 402-559-3814 






Roberts, Ellen phone: 402-559-4081 
degree: MD 
 
